- Home
- SGHT vs LXEO Comparison
SGHT vs LXEO Comparison
Compare SGHT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- LXEO
- Stock Information
- Founded
- SGHT 2011
- LXEO 2017
- Country
- SGHT United States
- LXEO United States
- Employees
- SGHT N/A
- LXEO N/A
- Industry
- SGHT Medical Specialities
- LXEO
- Sector
- SGHT Health Care
- LXEO
- Exchange
- SGHT Nasdaq
- LXEO Nasdaq
- Market Cap
- SGHT 140.1M
- LXEO 140.6M
- IPO Year
- SGHT 2021
- LXEO 2023
- Fundamental
- Price
- SGHT $2.25
- LXEO $2.95
- Analyst Decision
- SGHT Buy
- LXEO Strong Buy
- Analyst Count
- SGHT 7
- LXEO 5
- Target Price
- SGHT $3.83
- LXEO $22.80
- AVG Volume (30 Days)
- SGHT 270.5K
- LXEO 819.0K
- Earning Date
- SGHT 03-05-2025
- LXEO 05-08-2025
- Dividend Yield
- SGHT N/A
- LXEO N/A
- EPS Growth
- SGHT N/A
- LXEO N/A
- EPS
- SGHT N/A
- LXEO N/A
- Revenue
- SGHT $79,866,000.00
- LXEO N/A
- Revenue This Year
- SGHT $3.09
- LXEO N/A
- Revenue Next Year
- SGHT $13.61
- LXEO N/A
- P/E Ratio
- SGHT N/A
- LXEO N/A
- Revenue Growth
- SGHT N/A
- LXEO N/A
- 52 Week Low
- SGHT $2.17
- LXEO $2.32
- 52 Week High
- SGHT $8.45
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- SGHT 37.59
- LXEO 41.97
- Support Level
- SGHT $2.64
- LXEO $2.90
- Resistance Level
- SGHT $3.13
- LXEO $4.59
- Average True Range (ATR)
- SGHT 0.22
- LXEO 0.52
- MACD
- SGHT -0.05
- LXEO 0.06
- Stochastic Oscillator
- SGHT 6.38
- LXEO 22.41
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.